Monarch Capital Management Inc. Has $1.06 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Monarch Capital Management Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY) by 17.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,368 shares of the company’s stock after purchasing an additional 206 shares during the quarter. Monarch Capital Management Inc.’s holdings in Eli Lilly and Company were worth $1,056,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Beck Bode LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $15,036,000. XTX Topco Ltd bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $546,000. Pacer Advisors Inc. grew its position in shares of Eli Lilly and Company by 5.8% in the 2nd quarter. Pacer Advisors Inc. now owns 68,017 shares of the company’s stock valued at $61,581,000 after acquiring an additional 3,713 shares during the period. Westwood Holdings Group Inc. increased its position in Eli Lilly and Company by 1.9% during the second quarter. Westwood Holdings Group Inc. now owns 3,912 shares of the company’s stock worth $3,542,000 after buying an additional 73 shares during the last quarter. Finally, Kowal Investment Group LLC raised its stake in Eli Lilly and Company by 16.7% in the 2nd quarter. Kowal Investment Group LLC now owns 1,287 shares of the company’s stock valued at $1,165,000 after acquiring an additional 184 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $726.24 on Monday. Eli Lilly and Company has a 12 month low of $612.70 and a 12 month high of $972.53. The firm has a market capitalization of $689.43 billion, a PE ratio of 78.51, a price-to-earnings-growth ratio of 1.66 and a beta of 0.41. The firm has a fifty day simple moving average of $781.14 and a two-hundred day simple moving average of $854.35. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue was up 20.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 EPS. Analysts forecast that Eli Lilly and Company will post 13.14 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has authorized a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is presently 64.86%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on LLY. Truist Financial lifted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.